WHO ICTRP trial
PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER
EUCTR2004-004845-17-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2004-004845-17-IT |
|---|---|
| Public title | PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER |
| Scientific title | PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER |
| Primary sponsor | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | OVARIAN CANCER RECCURRENCE MedDRA version: 9.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| Interventions | Trade Name: GEMZAR*INFUS 1FL 1G POLV Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Gemcitabine CAS Number: 122111-03-9 Concentration unit: % percent Concentration type: equal Concentration number: 1- Trade Name: TAXOL… |
| Registration date | Aug 8, 2007 |
| Secondary IDs | A/616/04 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: